AirNexis Therapeutics

Series-A
airnexis.com Biotech & Healthcare Palo Alto, United States
Total Funding $200M
Latest Round $200M Series-A
Last Announced Jan 9, 2026
Investors 6 Backers
Decision Makers Profile Active

About AirNexis Therapeutics

AirNexis Therapeutics develops clinical-stage therapies for chronic obstructive pulmonary disease and other pulmonary conditions.

Company Details

Intelligence Dossier

Corporate & Operational Profile

Primary Industry Biotech & Healthcare
Funding Stage Series-A
Global Headquarters Palo Alto, United States
Tracked Since Nov 6, 2026

Web & Domain Identity

Official Website airnexis.com
Domain Registered Date Undisclosed

Social & Network Presence

X / Twitter Profile Not linked
LinkedIn Corporate Company Profile

Company Milestones & Timeline

1 Events
  1. Capital Raise

    Raised $200,000,000 · Series-A

    Backed by Frazier Life Sciences

Investors & Backers

6
Frazier Life Sciences
Lead
Enavate Sciences
Goldman Sachs Alternatives
Longitude Capital
OrbiMed
SR One

Funding History

1 Round
Series-A equity · Jan 9, 2026

Round backers: Frazier Life Sciences

Press Coverage & Sources

Recently Funded Biotech & Healthcare Startups

View all

Search the startup feeds free with 50 starter credits.

Recently funded startups
New SaaS launches
Never pay twice for contacts